Global Next-generation Transcatheter Aortic Valves Market Anticipated to Reach USD 4,011.6 Million by 2031

According to a recent market study published by Growth Market Reports, titled, Global Next-generation Transcatheter Aortic Valves Market by Product, Size, Indication, End-user, and Region: Size, Share, Trends and Opportunity Analysis, 2016-2031, the market was valued at USD 2,212.7 Million in 2022 and is anticipated to expand at a growth rate of 7.0% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6314

Transcatheter aortic valve replacement (TAVR) is a technique that involves replacing an aortic valve that has become restricted and is unable to fully open. The aortic valve connects the left lower heart chamber to the main artery of the body. Aortic valve stenosis refers to a narrowing of the aortic valve. Valve malfunction inhibits or slows blood flow from the heart to the body. TAVR is a minimally invasive method that makes smaller incisions than open-heart valve surgery.

It is possible for patients, who are unable to undergo heart surgery, to have their aortic valves replaced. TAVR helps relieve chest pain, shortness of breath, and other symptoms of aortic valve stenosis. Transcatheter aortic valve replacement is often referred to as transcatheter aortic valve implantation (TAVI).

The global Next-generation transcatheter aortic valves market is segmented in terms of product, size, indication, and end-user. In terms of product, the global Next-generation transcatheter aortic valves market is segregated into self-expandable valve, balloon-expandable valve, mechanically expandable valve, and non-metallic valve. On the basis of size, the market is fragmented into small, medium, and large. In terms of indication, the market is segregated into aortic stenosis and aortic valve regurgitation. Based on end-user, the market is separated into hospitals, specialty clinics, and others. In terms of region, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The outbreak of coronavirus disease in 2019 (COVID-19) had some negative effects on the global arterial Next-generation transcatheter aortic valves market. According to Cardiovascular Business magazine, 92,000 TAVR valves are expected to be implanted in patients across the US in 2021. The COVID-19 pandemic had a slight impact on the global economy and healthcare system. Major cardiovascular device manufacturers suffered significant revenue losses during the pandemic, as a result of disrupted medical device supply chains and a decrease in overall medical operation numbers.

Some hospitals and cardiac centers increased their adoption of Next-generation transcatheter aortic valves during the pandemic, which drove the market. Rising prevalence of aortic valve stenosis (AS), increased demand for minimally invasive procedures such as transcatheter aortic valve replacement (TAVR), and an aging population drive the market.

Key Takeaways from the Study:

• Players in the global new-generation transcatheter aortic valves market include Abbott, Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic, Genesis Medtech (JC Medical, Inc.), and others.

• Based on product, the global Next-generation transcatheter aortic valves market is segmented into self-expandable valve, balloon-expandable valve, mechanically expandable valve, and non-metallic valve.

• The self-expandable valve segment held a notable market share in 2022 and is projected to expand at a CAGR of xx% during the forecast period, due to its short–intermediate term. Self-expandable valves have improved valve hemodynamics, however, have higher PVL and PPM implantation rates than BEVs. Advances in transcatheter valve technologies and expanded indications for TAVR have resulted in improved outcomes for patients undergoing TAVR in the US who have self-expanding and supra-annular valves.

• On the basis of size, the global Next-generation transcatheter aortic valves market is separated into small, medium, and large. The small segment had a high revenue share in 2022. Small size is used in aortic valve surgery. For example, ACURATE neo is implanted using a dedicated 14F expandable introducer sheath. The valve is available in three sizes (small, medium, and large) to accommodate native aortic annulus diameters ranging from 21 to 27 mm.

• In terms of indication, the global Next-generation transcatheter aortic valves market is divided into aortic stenosis and aortic valve regurgitation. The aortic stenosis segment is expected to have a significant CAGR in the coming years, due to the rising prevalence of aortic stenosis in the US and Europe.

• Based on end-user, the global next-generation transcatheter aortic valves market is segregated into hospitals, specialty clinics, and others. The hospitals segment is projected to expand at a CAGR of XX% during the forecast period. Rising heart valve disorders result in a significant increase in the demand for heart surgery. Hospitals equipped with medical devices are well-adapted to meet this demand, as they provide faster and more reliable test results than traditional operating facilities. The increased demand for surgeries results in increasing revenue for hospitals.

• Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market in North America accounted for a XX% share of the market in 2022, owing to the rising prevalence of severe aortic stenosis in those aged ≥75 years is 3.4% in the US. Valvular disease primarily affects the elderly in developed countries. It develops gradually and is frequently associated with other comorbidities.

• Europe has witnessed an increase in the prevalence of lifestyle diseases and a rise in the elderly population, which is contributing to the market growth. Countries such as Germany, the UK, and France are the leading in this market, due to their highly developed healthcare systems and the presence of major market players.

Key Developments

• On September 16, 2022, Medtronic announced the full market launch in the US of the Evolut-FX Next-generation TAVR system for the treatment of symptomatic severe aortic stenosis. Evolut FX enhances the existing Evolut platform by introducing new features that make valve deployment easy and predictable for physicians. The Evolut FX system is expected to be available to all commercial TAVR sites in the US with this latest expansion.

Report Scope:

Target Audience:

• Supply-side: Manufacturers, Suppliers/Distributors and Logistics, End-users/Applications

• Regulatory Side: Concerned government authorities, and other approved regulatory bodies

  • • United States Food and Drug Administration (FDA)

    • World Health Organization (WHO)

    • European Union (EU) Medical Devices Directive (MDD)

    • International Organization for Standardization (ISO),

    • Central Drugs Standard Control Organization (CDSCO),

    • Department of Science and Technology (DST),

    • Centers for Disease Control and Prevention (CDC),

    • Others